Journal article

Clinical guidance for radioiodine refractory differentiated thyroid cancer

Matti L Gild, Duncan J Topliss, Diana Learoyd, Francis Parnis, Jeanne Tie, Brett Hughes, John P Walsh, Donald SA McLeod, Roderick J Clifton-Bligh, Bruce G Robinson

Clinical Endocrinology | WILEY | Published : 2018


Prognosis from differentiated thyroid cancer is worse when the disease becomes refractory to radioiodine. Until recently, treatment options have been limited to local therapies such as surgery and radiotherapy, but the recent availability of systemic therapies now provides some potential for disease control. Multitargeted kinase inhibitors (TKIs) including lenvatinib and sorafenib have been shown to improve progression-free survival in phase III clinical trials, but are also associated with a spectrum of adverse effects. Other TKIs have been utilized as "redifferentiation" agents, increasing sodium iodide symporter expression in metastases and thus restoring radioiodine avidity. Some patient..

View full abstract

University of Melbourne Researchers